{
    "nct_id": "NCT04414540",
    "official_title": "A Phase 2 Feasibility Study Combining Pembrolizumab and Metformin to Harness the Natural Killer Cytotoxic Response in Metastatic Head and Neck Cancer Patients",
    "inclusion_criteria": "* Histologically or cytologically confirmed recurrent or metastatic non-cutaneous HNSCC for which there are no surgical or radiation curative options.\n* Patients may have received up to 3 prior lines of therapy for metastatic or recurrent disease.\n* ECOG performance status â‰¤2\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "* Patients with nasopharyngeal HNSCC will be excluded\n* Patients who have had chemotherapy or radiotherapy within 2 weeks prior to entering the study.\n* Patients who have not recovered from adverse events due to prior anti-cancer therapy\n* Patients who have previously received PD-1 or PD-L1 inhibitors for metastatic/recurrent disease\n* Patients currently receiving metformin or who have received metformin in the last 6 months",
    "miscellaneous_criteria": ""
}